1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

More documents

Recommendations

Info

13. Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, GoldeDW, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dosecyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemiaproduces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol27(4): 491-7, 2009. PMID: 1907528014. Santos EB, Yeh R, Lee J, NIkhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M,Brentjens RJ. Sensitive in vivo imaging of T cells utilizing a membrane bound Gaussia princeps luciferase.Nat Med 15 (3):338-44, 2009. PMID: 1921902315. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V,Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Riviere I. Manufacturing validation of biologicallyfunctional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32: 169-80,2009. PMID: 1923801616. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia withgenetically targeted autologous T cells: A case report of an unforeseen adverse event in a phase I clinical trial.Mol Ther 18:666-8, 2010. PMID: 2035777917. Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan MT,Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, van den Brink MR. Concurrentvisualization of T lymphocytes and T cell precursors in vivo. Blood. 2010 Sep 16;116(11):e18-25. Epub 2010May 28. PMID: 2051154118. Lee J, Hayman E, Pegram H, Santos E, Heller G, Sadelain M, Brentjens RJ. In vivo inhibition of humanCD19 targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cellmalignancy. Can Res (in press).19. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. Successfuleradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cellsgenetically targeted to the MUC16 antigen. Clin Can Res 16:3594-606, 2010 PMID: 2062803020. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M. CARson Track in the Clinic. Heslop HE. Mol Ther. 2011 Mar;19(3):432-8. PMID: 2135870521. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo Inhibition of HumanCD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B CellMalignancy. Cancer Res. 2011 Apr 15;71(8):2871-81. Epub 2011 Apr 12. PMID: 2148703822. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, HoseyJ, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safetyand persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed orchemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. Epub 2011 Aug 17. PMID:2184948623. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.Tumor-targeted T cellsmodified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Feb 21.[Epub ahead of print] PMID:2235400116
1. Books, book chapters and reviews1. Brentjens RJ, Saltz L. Islet cell tumors of the pancreas: The medical oncologist’s perspective. Surg. Clin.North Am. 81:527-542, 2001. PMID: 114592692. Brentjens R, Saltz L. Epidermal growth factor receptor blockade and the treatment of solid tumormalignancies. In Progress in Oncology 2002. VT DeVita, S Hellman, SA Rosenberg, eds. Sudbury: Jonesand Bartlett Publishers, 2003:113-128.3. Sadelain M, Riviere I, and Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat.Rev. Can. 3:35-45, 2003. PMID: 125097654. Brentjens R, Sadelain M. Somatic cell engineering and the Immunotherapy of Leukemias and Lymphomas.Advances Pharmacol. 51:347-70, 2004. PMID: 154649175. Riviere I, Sadelain M, Brentjens R. Novel Strategies for cancer therapy: The potential of genetically modifiedT lymphocytes. Curr Hematol Rep 3:290-297, 2004. PMID: 152175596. Brentjens R, Weiss M. Chronic leukemias. In Conn’s Current Therapy. Rakel, Bope eds. Philadelphia:Elsevier, 2005: 514-521.7. Brentjens R. Novel approaches to immunotherapy for B cell malignancies. Curr Oncol Rep. 6(5):339-47,2004. [Reprinted in Curr Hematol Rep. 2005 Jan;4(1):64-72]. PMID: 152919748. Brentjens RJ. Novel approaches to immunotherapy for B cell malignancies: An update. Curr. Hematol.Malig. Rep. 1, 258-63, 2006. PMID: 20453219. Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T cells. Methods in MolecularMedicine 506:83-96, 2009. PMID: 1911062110. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr.Opin. Immunology 21:1-9, 2009. PMID: 1932797411. Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Curr. Opin. Mol. Ther. 11:375-82, 2009.PMID: 1964998212. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients withovarian cancer. Discov Med. 9:62-70 2010. PMID: 2010268813. Park J, Brentjens RJ. Adoptive immunotherapy for B cell malignancies with autologous chimeric antigenreceptor modified tumor targeted T cells. Discov Med 9:277-88 2010. PMID: 2042367114. Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol ClinNorth Am. 2011 Dec; 25(6):1281-301. [PubMed - indexed for MEDLINE] PMID: 2209358715. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: currentunderstanding and future direction. J Gene Med. 2012 Jun;14(6):405-15.doi: 10.1002/jgm.2604. PMID:2226264917
Page 1 and 2: Memorial Sloan-Kettering Cancer Cen
Page 3 and 4: 3. Hospital positions (e.g., attend
Page 5 and 6: Kendrick Kelly History Scholar 1988
Page 7 and 8: Sarwish Rafiq PhD; Role: Post Doc F
Page 9 and 10: Experimental Therapeutics Center Pr
Page 11 and 12: 3/29/2009 “Adoptive T cell therap
Page 13 and 14: 10/19/2012 “Chimeric antigen rece
Page 15: L. BIBLIOGRAPHY1. Brentjens RJ, Spi
Page 19 and 20: 11. R. Brentjens, E. Santos, R. Yeh
Page 21 and 22: 35. M.L. Davila, C.Taylor, X.Wang,
Page 23: 56. E. Halton, D. Chung, K. Xiao, H

1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?